Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | DRD3 | P35462 | 6/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480724 | 0.83 | DRD1 (0.39) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL9535672 | 0.77 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL5776171 | 0.77 | HTR1A (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4932570 | 0.76 | L3MBTL1 (0.37) | DRD2DRD4DRD3 | |
| SCHEMBL14112792 | 0.76 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL27499177 | 0.76 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8880016 | 0.76 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407496 | 0.75 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15211143 | 0.75 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL16428909 | 0.75 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039639-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039639-A1 | Chromane and chromene derivatives and uses thereof | HTR1A, CHRM1, HTR2C | CA2 2360/4885HTR1A 1/4885SIGMAR1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.